Post‐hoc analysis on the long‐term response to fixed‐dose prophylaxis with N8‐GP in patients with haemophilia A
Open Access
- 25 September 2021
- journal article
- research article
- Published by Wiley in Haemophilia
- Vol. 28 (1) , 27-35
Abstract
Introduction Challenges with personalised prophylaxis in haemophilia remain, including designing unique dosing schedules that require continual adjustments and monitoring using complex sampling procedures. Aim To assess long-term efficacy and pharmacokinetic outcomes with fixed-dose N8-GP prophylaxis. Methods Descriptive analyses were performed on data from the pathfinder 2 and pathfinder 5 trials of patients with severe haemophilia A. Bleed frequency and reoccurrence were assessed in relation to several clinical criteria of interest. Bleed risk relative to time since last dose was assessed using calculated annualised bleeding rate (ABR). Long-term ABR and mean factor VIII (FVIII) trough levels were assessed in patients who received consistent N8-GP prophylaxis every 4 days (Q4D). Results During pathfinder 2, 117/136 patients with study-drug exposure of ≥600 days experienced bleeding episodes; 8.6% of bleeds were reoccurring bleeds; bleed reoccurrence decreased over time. For patients who received consistent Q4D prophylaxis across the trial (n = 61), mean ABR decreased from 3.5 bleeds/year (Year 1) to 1.6 bleeds/year (Year 6); mean FVIII trough levels stabilised at approximately 5% (Year 6). Across patients who received prophylaxis at some point during pathfinder 2 (n = 177), 125/126 (99%) reoccurring bleeds were joint bleeds. For patients receiving Q4D prophylaxis, bleeding risk generally increased as the time since the last prophylaxis dose increased. A similar reduction in ABR and stabilisation of trough level was observed in pathfinder 5. Conclusion Long-term exposure (> 5 years) to fixed-dose N8-GP prophylaxis resulted in a protective haemostatic effect, with reduction in bleed frequency and reoccurrence, and stabilisation of FVIII trough level over time.Keywords
This publication has 16 references indexed in Scilit:
- Extended half-life recombinant products in haemophilia clinical practice – Expectations, opportunities and challengesThrombosis Research, 2020
- Long‐term safety and efficacy of N8‐GP in previously treated adults and adolescents with hemophilia A: Final results from pathfinder2Journal of Thrombosis and Haemostasis, 2020
- Recombinant factor VIII Fc fusion protein for the treatment of severe haemophilia A: Final results from the ASPIRE extension studyHaemophilia, 2020
- BAY 94‐9027 prophylaxis is efficacious and well tolerated for up to >5 years with extended dosing intervals: PROTECT VIII extension interim resultsHaemophilia, 2019
- Once‐weekly prophylaxis with glycoPEGylated recombinant factor VIII (N8‐GP) in severe haemophilia A: Safety and efficacy results from pathfinder 2 (randomized phase III trial)Haemophilia, 2019
- Hemophilia Care in the Pediatric AgeJournal of Clinical Medicine, 2017
- Clinical evaluation of glycoPEGylated recombinant FVIII: Efficacy and safety in severe haemophilia AThrombosis and Haemostasis, 2017
- Personalized prophylaxis in people with hemophilia A: challenges and achievementsExpert Review of Hematology, 2016
- The past and future of haemophilia: diagnosis, treatments, and its complicationsThe Lancet, 2016
- Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia ABlood, 2014